# Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma

> **NCT03149822** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 45 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03149822
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-28
- **Primary completion:** 2022-12-14
- **Final completion:** 2024-02-16
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03149822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03149822, "Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03149822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*